Immune-Activated B Cells Are Dominant in Prostate Cancer.

B cells T cells prostatic neoplasms sentinel lymph node biopsy

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
01 Feb 2023
Historique:
received: 10 12 2022
revised: 22 01 2023
accepted: 29 01 2023
entrez: 11 2 2023
pubmed: 12 2 2023
medline: 12 2 2023
Statut: epublish

Résumé

B cells are multifaceted immune cells responding robustly during immune surveillance against tumor antigens by presentation to T cells and switched immunoglobulin production. However, B cells are unstudied in prostate cancer (PCa). We used flow cytometry to analyze B-cell subpopulations in peripheral blood and lymph nodes from intermediate-high risk PCa patients. B-cell subpopulations were related to clinicopathological factors. B-cell-receptor single-cell sequencing and VDJ analysis identified clonal B-cell expansion in blood and lymph nodes. Pathological staging was pT2 in 16%, pT3a in 48%, and pT3b in 36%. Lymph node metastases occurred in 5/25 patients (20%). Compared to healthy donors, the peripheral blood CD19

Identifiants

pubmed: 36765877
pii: cancers15030920
doi: 10.3390/cancers15030920
pmc: PMC9913271
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Uppsala Multidisciplinary Center for Advanced Computational Science
ID : SNIC 2019/8-143 and uppstore2019-30-9
Organisme : Vetenskapsrådet
ID : 2022-5-18
Organisme : Sveriges Regering
ID : RV-970150

Références

J Transl Med. 2014 Jan 30;12:30
pubmed: 24475900
Nat Commun. 2021 Feb 10;12(1):935
pubmed: 33568675
NPJ Breast Cancer. 2018 Aug 23;4:28
pubmed: 30155518
Proc Natl Acad Sci U S A. 2014 Oct 14;111(41):14776-81
pubmed: 25267627
J Immunol. 2010 Nov 1;185(9):4977-82
pubmed: 20962266
J Immunol. 2008 Feb 1;180(3):1362-72
pubmed: 18209030
Eur J Cancer Care (Engl). 2008 Jul;17(4):404-11
pubmed: 18485013
Eur Urol Focus. 2018 Jan;4(1):75-79
pubmed: 28753790
Clin Cancer Res. 2011 Jul 1;17(13):4550-7
pubmed: 21498393
Cell. 2015 May 21;161(5):1215-1228
pubmed: 26000489
Adv Exp Med Biol. 2006;587:341-74
pubmed: 17163176
Clin Cancer Res. 2015 Aug 15;21(16):3619-30
pubmed: 25649018
Nature. 2013 Jul 11;499(7457):214-218
pubmed: 23770567
Nat Rev Immunol. 2015 Jul;15(7):441-51
pubmed: 26065586
Medicina (B Aires). 2014;74(3):185-8
pubmed: 24918664
Immunity. 2001 Feb;14(2):111-21
pubmed: 11239444
Scand J Immunol. 2020 Feb;91(2):e12830
pubmed: 31823416
J Exp Med. 2021 Jan 4;218(1):
pubmed: 33601413
Mol Biol Rep. 2018 Dec;45(6):2935-2940
pubmed: 30311129
J Oncol. 2019 Sep 24;2019:2592419
pubmed: 31662750
Cancers (Basel). 2021 Jan 24;13(3):
pubmed: 33498854
Sci Rep. 2015 Jul 20;5:12255
pubmed: 26193241
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Nature. 2015 May 7;521(7550):94-8
pubmed: 25924065
Afr Health Sci. 2020 Sep;20(3):1264-1272
pubmed: 33402974
J Natl Cancer Inst. 2019 Mar 1;111(3):301-310
pubmed: 30321406
Cytometry B Clin Cytom. 2008 Sep;74(5):261-71
pubmed: 18561200
Cancer Immunol Immunother. 2009 Oct;58(10):1535-44
pubmed: 19562338
J Immunol. 2009 Feb 15;182(4):1868-76
pubmed: 19201839
Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14639-45
pubmed: 15381769
Cell. 2015 Nov 5;163(4):1011-25
pubmed: 26544944
Nat Rev Cancer. 2012 Mar 22;12(4):278-87
pubmed: 22437872
Nature. 2010 Mar 11;464(7286):302-5
pubmed: 20220849
Int J Mol Sci. 2014 Nov 05;15(11):20209-39
pubmed: 25380524
Oncogene. 2010 Feb 25;29(8):1093-102
pubmed: 19946335
Cancer Res. 2011 Sep 1;71(17):5601-5
pubmed: 21846822
J Exp Med. 1996 Mar 1;183(3):1161-72
pubmed: 8642258
J Immunol. 2009 Sep 1;183(5):3195-203
pubmed: 19667089
PLoS Med. 2019 Mar 12;16(3):e1002758
pubmed: 30860997
Eur Urol. 2010 Jul;58(1):105-11
pubmed: 19766386
J Immunol. 2005 Aug 1;175(3):1424-32
pubmed: 16034078
N Engl J Med. 2016 Aug 4;375(5):443-53
pubmed: 27433846
J Immunol. 2013 Jun 1;190(11):5847-55
pubmed: 23630345
Science. 2015 Apr 3;348(6230):56-61
pubmed: 25838373
Lancet Oncol. 2006 Dec;7(12):1006-16
pubmed: 17138222
PLoS Med. 2016 Aug 02;13(8):e1002063
pubmed: 27483464

Auteurs

Aws Saudi (A)

Department of Urology, Medical Faculty, Linköping University, 581 85 Linköping, Sweden.
Department of Clinical and Experimental Medicine, Medical Faculty, Linköping University, 581 85 Linköping, Sweden.

Viqar Banday (V)

Department of Surgical and Perioperative Sciences, Urology and Andrology, Umea University, 901 85 Umea, Sweden.
Department of Clinical Microbiology, Immunology, Umea University, 901 85 Umeå, Sweden.

A Ali Zirakzadeh (AA)

Immuneed AB, 753 41 Uppsala, Sweden.

Martin Selinger (M)

The Laboratory for Molecular Infection Medicine Sweden (MIMS), 901 87 Umeå, Sweden.
Department of Molecular Biology, Umeå Centre for Microbial Research, 6K and 6L, Umeå University, 901 87 Umeå, Sweden.

Jon Forsberg (J)

Department of Urology, Medical Faculty, Linköping University, 581 85 Linköping, Sweden.

Martin Holmbom (M)

Department of Urology, Medical Faculty, Linköping University, 581 85 Linköping, Sweden.

Johan Henriksson (J)

The Laboratory for Molecular Infection Medicine Sweden (MIMS), 901 87 Umeå, Sweden.
Department of Molecular Biology, Umeå Centre for Microbial Research, 6K and 6L, Umeå University, 901 87 Umeå, Sweden.

Mauritz Waldén (M)

Department of Urology, Central Hospital of Karlstad, 652 30 Karlstad, Sweden.

Farhood Alamdari (F)

Department of Urology, Västmanland Hospital, 721 89 Västerås, Sweden.

Firas Aljabery (F)

Department of Urology, Medical Faculty, Linköping University, 581 85 Linköping, Sweden.
Department of Clinical and Experimental Medicine, Medical Faculty, Linköping University, 581 85 Linköping, Sweden.

Ola Winqvist (O)

ABClabs, BioClinicum, Campus Solna, 171 76 Stockholm, Sweden.

Amir Sherif (A)

Department of Surgical and Perioperative Sciences, Urology and Andrology, Umea University, 901 85 Umea, Sweden.

Classifications MeSH